B. Riley analyst Mayank Mamtani raised the firm’s price target on Novavax (NVAX) to $29 from $11 and keeps a Buy rating on the shares. The recent strategic collaboration and licensing agreement with Sanofi (SNY) is broadly viewed as a long-awaited inflection point, the analyst tells investors in a research note. The price target increase is driven by an even more streamlined opex structure focused primarily on enhancing Matrix M adjuvant-based pipeline productivity, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Shah Capital Ends Proxy Fight at Novavax After Sanofi Deal Boost
- Novavax call volume above normal and directionally bullish
- Novavax shareholder Shah Capital withdraws campaign against director re-election
- Biotech Alert: Searches spiking for these stocks today
- Largest borrow rate increases among liquid names
